Logotype for Silex Systems Limited

Silex Systems (SLX) H2 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Silex Systems Limited

H2 2025 earnings summary

31 Mar, 2026

Executive summary

  • Achieved significant progress in commercialising SILEX laser-based uranium enrichment technology, with large-scale pilot demonstration (TRL-6) underway at GLE's Wilmington, NC facility and expected to complete by end of 2025, subject to independent assessment.

  • GLE acquired a 700-acre site in Paducah, KY for the planned Paducah Laser Enrichment Facility (PLEF), securing access to DOE's depleted uranium tails for up to 30 years of feedstock.

  • GLE selected as one of six awardees under the US DOE's LEU Enrichment Acquisition program, with initial $0.5m awarded and potential to bid for up to $900m in further funding.

  • Construction of the first full-scale Quantum Silicon (Q-Si) production plant module advanced, targeting the emerging quantum computing market.

  • Completed $130m institutional placement in August 2025 to support US commercialisation, isotope enrichment opportunities, and working capital.

Financial highlights

  • Revenue from continuing operations was $12.2m, down from $12.9m in the prior year, mainly due to lower interest revenue.

  • Net loss increased to $42.6m from $22.7m, primarily due to a $18.5m increase in Silex's 51% share of GLE's loss, reflecting higher GLE operating expenditures.

  • Other income rose to $6.4m, driven by higher R&D tax incentives and government grants.

  • Net assets at 30 June 2025 were $90.9m, down 31% from the prior year, with cash holdings of $80.6m and no corporate debt.

  • Earnings per share was a loss of 17.9 cents, compared to a loss of 9.6 cents in the prior year.

Outlook and guidance

  • GLE aims to complete TRL-6 pilot demonstration by end of 2025, with commercial operations at PLEF targeted no later than 2030, subject to successful validation, regulatory approval, and market conditions.

  • Ongoing focus on expanding SILEX technology applications in uranium enrichment, quantum silicon, and medical isotopes.

  • Potential for significant US government funding and industry partnerships to support commercialisation.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more